Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Artemether/lumefantrine - Novartis

X
Drug Profile

Artemether/lumefantrine - Novartis

Alternative Names: Benflumetol; CGP 56697; Co-artemether; COA566; Coartem; Coartem Dispersible; Exafal; Lumefantrine/artemether; Riamet

Latest Information Update: 29 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Academy of Military Medical Sciences (Beijing)
  • Developer Medicines for Malaria Venture; Novartis
  • Class Anthelmintics; Antifungals; Antimalarials; Antiprotozoals; Artemisinins; Ethanolamines; Fluorenes; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Carrier protein inhibitors; Hemozoin inhibitors; Mitochondrial protein inhibitors; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malaria
  • New Molecular Entity No

Highest Development Phases

  • Marketed Malaria

Most Recent Events

  • 25 Apr 2024 Interim pharmacokinetics data from a phase II/III CALINA trial on malaria released by Novartis
  • 31 Mar 2024 Preregistration for Malaria (In neonates, In infants) in Switzerland (PO), before March 2024
  • 28 Apr 2022 Novartis plans to submit first regulatory application for Malaria in Switzerland in 2024
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top